Active VGF Nerve Growth Factor Inducible (VGF) Homo sapiens (Human) Active protein

NERP1; NERP2; Neuro-Endocrine Specific Protein VGF; Neuroendocrine Regulatory Peptide

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 80%
  • Isoelectric Point4.4
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active VGF Nerve Growth Factor Inducible (VGF) Packages (Simulation)
  • Active VGF Nerve Growth Factor Inducible (VGF) Packages (Simulation)
  • APB166Hu03.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Neurosecretory protein VGF is specifically expressed in a subpopulation of neuroendocrine cells, and is upregulated by nerve growth factor. Human VGF precursor is 615 amino acids (aa) in length. It contains an 22 aa signal sequence plus a 593 aa mature region. The structural organization of this gene is similar to that of the rat gene, and both the translated and the untranslated regions show a high degree of sequence similarity to the rat gene. The encoded secretory protein also shares similarities with the secretogranin/chromogranin family, however, its exact function is not known. Besides,VGF can affect the downstream signal transduction process of BDNF through its derived peptides, and affect the biological effects mediated by BDNF, such as neurodevelopment and synaptic plasticity., thus a binding ELISA assay was conducted to detect the interaction of recombinant human VGF and recombinant human BDNF. Briefly,biotin-linked VGF were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μl were then transferred to BDNF-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 30min, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µl stop solution to the wells and read at 450nm immediately. The binding activity of VGF and BDNF was shown in Figure 1, the EC50 for this effect is 0.066ug/mL.

Usage

Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Proteomic analysis of cerebrospinal fluid from obese women with idiopathic intracranial hypertension: a new approach for identifying new candidates in the pathogenesis of obesityPubMed: 22296024
  • Low VGF is associated with executive dysfunction in patients with major depressive disorderPubmed:35738161

Recommend products